Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Deferred Revenue (2018 - 2023)

Rocket Pharmaceuticals' Current Deferred Revenue history spans 6 years, with the latest figure at $597000.0 for Q2 2023.

  • For Q2 2023, Current Deferred Revenue changed 0.0% year-over-year to $597000.0; the TTM value through Jun 2023 reached $597000.0, changed 0.0%, while the annual FY2022 figure was $597000.0, 0.0% changed from the prior year.
  • Current Deferred Revenue for Q2 2023 was $597000.0 at Rocket Pharmaceuticals, roughly flat from $597000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $597000.0 in Q1 2021 and bottomed at $541000.0 in Q1 2019.
  • The 5-year median for Current Deferred Revenue is $597000.0 (2021), against an average of $583000.0.
  • The largest annual shift saw Current Deferred Revenue rose 5.46% in 2019 before it changed 0.0% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $562000.0 in 2019, then rose by 4.98% to $590000.0 in 2020, then rose by 1.19% to $597000.0 in 2021, then changed by 0.0% to $597000.0 in 2022, then changed by 0.0% to $597000.0 in 2023.
  • Per Business Quant, the three most recent readings for RCKT's Current Deferred Revenue are $597000.0 (Q2 2023), $597000.0 (Q1 2023), and $597000.0 (Q4 2022).